Patents Assigned to Gamida Cell Ltd.
  • Patent number: 11746325
    Abstract: Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded populations of CD133+/CD34+ cord blood cells for transplantation to subjects in need thereof and the therapeutic use of suitable selected, ex-vivo expanded CD133+/CD34+ and unselected CD133/CD34 negative cord blood fractions for transplantation in the clinical setting, for treatment of hematological malignancies are provided. The present invention also envisions kits comprising the expanded and unselected cord blood fractions.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: September 5, 2023
    Assignee: Gamida Cell Ltd.
    Inventors: Tony Peled, Einat Galamidi Cohen, David Snyder
  • Publication number: 20230242883
    Abstract: Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising culture NK cells and therapeutic uses thereof.
    Type: Application
    Filed: April 6, 2023
    Publication date: August 3, 2023
    Applicant: Gamida Cell Ltd.
    Inventors: Tony PELED, Gabi M. FREI
  • Publication number: 20200172863
    Abstract: Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded populations of CD133+/CD34+ cord blood cells for transplantation to subjects in need thereof and the therapeutic use of suitable selected, ex-vivo expanded CD133+/CD34+ and unselected CD133/CD34 negative cord blood fractions for transplantation in the clinical setting, for treatment of hematological malignancies are provided. The present invention also envisions kits comprising the expanded and unselected cord blood fractions.
    Type: Application
    Filed: May 16, 2017
    Publication date: June 4, 2020
    Applicant: Gamida Cell Ltd.
    Inventors: Tony PELED, Einat Galamidi COHEN, David SNYDER
  • Patent number: 10047345
    Abstract: Methods of culturing mesenchymal stem cells are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide and fibroblast growth factor 4 (FGF4). Populations of mesenchymal stem cells generated using the methods described herein and uses thereof are also provided.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: August 14, 2018
    Assignee: Gamida-Cell Ltd.
    Inventors: Tony Peled, Yair Steinhardt
  • Patent number: 9567569
    Abstract: A method of culturing mesenchymal stem cells (MSCs) is provided. The method comprising culturing a population of the MSCs in a medium comprising an aryl hydrocarbon receptor antagonist, thereby culturing MSCs.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: February 14, 2017
    Assignee: Gamida Cell Ltd.
    Inventors: Tony Peled, Yair Steinhardt
  • Patent number: 9175266
    Abstract: Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with an aryl hydrocarbon antagonist in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: November 3, 2015
    Assignee: Gamida Cell Ltd.
    Inventors: Tony Peled, Gabi M. Frei
  • Patent number: 8986992
    Abstract: Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: March 24, 2015
    Assignee: Gamida Cell Ltd.
    Inventor: Tony Peled
  • Publication number: 20150004146
    Abstract: Methods of culturing mesenchymal stem cells are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide and fibroblast growth factor 4 (FGF4). Populations of mesenchymal stem cells generated using the methods described herein and uses thereof are also provided.
    Type: Application
    Filed: February 13, 2012
    Publication date: January 1, 2015
    Applicant: Gamida-Cell Ltd.
    Inventors: Tony Peled, Yair Steinhardt
  • Patent number: 8846393
    Abstract: A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: September 30, 2014
    Assignee: Gamida-Cell Ltd.
    Inventor: Tony Peled
  • Publication number: 20130209414
    Abstract: Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof.
    Type: Application
    Filed: April 17, 2012
    Publication date: August 15, 2013
    Applicant: Gamida Cell Ltd.
    Inventor: Tony Peled
  • Publication number: 20130011376
    Abstract: Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof.
    Type: Application
    Filed: December 29, 2010
    Publication date: January 10, 2013
    Applicant: GAMIDA CELL LTD.
    Inventors: Tony Peled, Gabi M. Frei
  • Patent number: 8202724
    Abstract: A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells. The method comprises ex-vivo providing the stem cells with conditions for cell proliferation and with at least one copper chelator in an amount and for a time period for permitting the stem cells to proliferate and, at the same time, for reducing a capacity of the stem cells to differentiate.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: June 19, 2012
    Assignees: Gamida Cell Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Tony Peled, Eitan Fibach, Avi Treves
  • Publication number: 20120141434
    Abstract: A method and criteria are provided for selecting expanded hematopoietic stem cell populations for allogenic transplantation, the selected cell populations having high probability of engraftment and positive clinical outcome.
    Type: Application
    Filed: May 5, 2010
    Publication date: June 7, 2012
    Applicant: Gamida Cell Ltd.
    Inventors: Tony Peled, Dorit Harati
  • Patent number: 8187876
    Abstract: Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: May 29, 2012
    Assignee: Gamida Cell Ltd.
    Inventor: Tony Peled
  • Patent number: 8080417
    Abstract: Methods of ex-vivo expansion and at the same time inhibiting differentiation of stem cells by co-culture with mesenchymal cells, transplantable populations of renewable progenitor and stem cells expanded thereby, and their uses in therapeutic applications.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: December 20, 2011
    Assignee: Gamida-Cell Ltd.
    Inventors: Tony Peled, Arik Hasson
  • Patent number: 7955852
    Abstract: Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: June 7, 2011
    Assignee: Gamida Cell Ltd.
    Inventors: Tony Peled, Avi Treves, Oren Rosen
  • Publication number: 20110045589
    Abstract: A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells.
    Type: Application
    Filed: October 6, 2010
    Publication date: February 24, 2011
    Applicants: Gamida Cell LTD., Hadasit Medical Research Services And Development LTD.
    Inventors: Tony Peled, Eitan Fibach, Avi Treves
  • Publication number: 20110033427
    Abstract: Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.
    Type: Application
    Filed: October 20, 2010
    Publication date: February 10, 2011
    Applicant: Gamida Cell LTD.
    Inventors: Tony Peled, Avi Treves, Oren Rosen
  • Patent number: 7855075
    Abstract: A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: December 21, 2010
    Assignees: Gamida Cell Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Tony Peled, Eitan Fibach, Avi Treves
  • Patent number: 7655225
    Abstract: Ex vivo and in vivo methods of expanding a population of stem and/or progenitor cells, while at the same time reversibly inhibiting differentiation of the stem and/or progenitor cells by providing the stem and/or progenitor cells with an effective amount of at least one copper chelate, so as to maintain a free copper concentration available to said cells substantially unchanged, to thereby expand the population of said stem and/or progenitor cells, while at the same time reversibly inhibit differentiation of said stem and/or progenitor cells.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: February 2, 2010
    Assignee: Gamida Cell, Ltd.
    Inventors: Tony Peled, Avi Treves, Oren Rosen